Novartis Canada, Clarius Partner for Psoriatic Arthritis Care in Canada

Novartis Canada, Clarius Partner for Psoriatic Arthritis Care in Canada

By, Admin 30 May 2024

Overview

Novartis Pharmaceuticals Canada Inc. announced a partnership with Clarius Mobile Health (Clarius) as part of a dedicated effort to aid in early detection of psoriatic arthritis in Canada. By improving access to ultrasound technology, rheumatologists will be able to identify diagnostic markers sooner, and may positively impact the timeline to diagnosis for PsA patients.

Words from President: Novartis Canada

  • “At Novartis, we recognize the tremendous potential AI holds for our industry and the healthcare landscape at large,” said Mark Vineis, country president at Novartis Canada. 
  • “The partnership with Clarius has the potential to transform PsA detection, with the possibility of scaling to other Immunology indications, across specialties and beyond Canada.”

Works for Improving Accessibility to Medical Imaging

  • Novartis and Clarius share a commitment to improving accessibility to medical imaging in Canada. 
  • This agreement will facilitate access to handheld ultrasound devices for rheumatologists and deliver a robust training, support and education journey through in-person, virtual and asynchronous events. 
  • As a result of the partnership, Novartis will generate evidence to measure and monitor adoption, usage and impact, and determine how usage of ultrasound in routine practice is related to early detection of PsA.

From Vancouver General Hospital

  • “The use of point-of-care ultrasound empowers us as rheumatologists to aid in patient education and adherence, as well as therapeutic confidence, to significantly enhance patient care,” said Dr. Mohammad Bardi, clinical instructor at the University of British Columbia and Staff Rheumatologist, Vancouver General Hospital. 
  • “The Clarius handheld ultrasound enables us to provide the best care possible, especially in settings where access to the sizeable cart-based ultrasound systems is not readily available.”

Clarius

  • Clarius is a pioneer in the medical device field, miniaturizing ultrasound technology to improve medical imaging accessibility. 
  • Approved by Health Canada in 2022, the third generation Clarius HD3 boasts a product line of high-performance handheld ultrasound scanners that wirelessly connect to clinician Apple and Android smart devices with an AI-powered application. 
  • The Clarius app uses advanced artificial intelligence technology to automatically display an optimized image in real-time, enabling clinicians to make informed decisions at the point of care rather than referring patients to an imaging centre.

Words from CEO: Clarius

  • “We are inspired by Novartis’ mission to improve care for PsA patients and their novel approach to help accelerate diagnosis with real-time ultrasound imaging,” said Ohad Arazi, president and CEO at Clarius. 
  • “We believe that this type of partnership between a pharmaceutical and a medical technology company can play a tremendous role in improving patient outcomes and reducing the burden on our healthcare system.

Novartis

  • Novartis is a focused innovative medicines company. 
  • Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.

Clarius

  • Clarius is on a mission to make accurate, easy-to-use, and affordable ultrasound tools available to all medical professionals in every specialty. 
  • With decades of experience in medical imaging, the team knows that great ultrasound imaging improves confidence and patient care.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!